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Abstract
Taenia solium causes neurocysticercosis, a parasitic infection of the central 
nervous system in humans. The costs of management, treatment, and diagnosis of 
patients with neurocysticercosis are high, and some patients do not respond to the 
currently available treatments. Helminth cytosolic glutathione transferases (GSTs) 
are essential enzymes involved in the regulation of immune responses, transport, 
and detoxification. In T. solium, three cytosolic GSTs with molecular masses of 26.5 
(Ts26GST), 25.5 (Ts25GST), and 24.3 kDa (TsMσGST), classified as mu-alpha, mu 
and sigma GST-classes, respectively, constitute the main detoxification system, and 
they may be immune targets for the development of vaccines and new anthelmin-
tics. We performed a successful virtual screen, and identified I7, a novel selective 
inhibitor of Ts26GST that showed a non-competitive inhibition mechanism towards 
substrate glutathione with a Ki of 55.7 mM and mixed inhibition towards the 
electrophilic substrate 1-chloro-2,4-dinitrobenzene with a Ki of 8.64 mM. Docking 
simulation studies showed that I7 can bind to a site that is adjacent to the electro-
philic site and the furthest from the glutathione site. This new inhibitor of Ts26GST 
will be used as a lead molecule to develop new effective and safe drugs against 
diseases caused by T. solium.
Keywords: Glutathione transferase, Inhibitor, Taenia solium, Neurocysticercosis
1. Introduction
1.1 Neurocysticercosis
Taenia solium is a cestode parasite in humans. Adult parasites cause taeniasis, and 
the larvae cause cysticercosis. Larvae located in the central nervous system cause 
neurocysticercosis (NCC), with a wide spectrum of clinical manifestations that 
depend on factors such as the location, number of larvae, and the intensity of host 
immune response [1, 2]. The disease may be asymptomatic or present with nonspe-
cific symptoms, such as epilepsy, cognitive impairment, migraine-type headache, 
intracranial hypertension, and neurological deficits, among other symptoms [3, 4].
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1.2 Clinical spectrum
According to the location of the larvae, NCC is classified into parenchymal NCC 
and extraparenchymal NCC. In the parenchymal NCC, the most frequent symptoms 
are seizures, which can occur at any stage of the cysticercus (viable or calcified) [5], 
and neurological signs, such as sensory deficits, language, and gait disturbances, as 
well as involuntary movements. Such manifestations have been reported in up to 
15% of patients [3]. In the extraparenchymal NCC, cysticerci are usually found in the 
subarachnoid and ventricular locations. Hydrocephalus is observed in a significant 
number of cases of subarachnoid NCC, and neurological alterations associated with 
the obstruction of the cerebrospinal fluid flow have been observed in patients with 
ventricular NCC; the blockage of the cerebral aqueduct due to the presence of cysticerci 
in the fourth ventricle may result in the loss of consciousness or even death [3, 6, 7].
1.3 Treatment
NCC is a disease transmitted by food, which causes many disability-adjusted life 
years. In Mexico, the cost of management, treatment, and diagnosis of patients with 
NCC was approximately U.S. $52 million in 2015 [8]. In addition to these costs, a 
study in Peru estimated that two-thirds of patients who develop symptoms lose their 
jobs, and the sequelae make it impossible for 60% of them to return to work [9]. 
Treatment should be individualized according to the characteristics of the disease 
and location of cysticerci, but in general, it consists of a mixture of surgical inter-
vention (recommended for cases of intraventricular or spinal NCC), antiparasitic 
and anti-inflammatory drugs, and drugs for the management of symptoms [10]. The 
antiparasitic treatment for NCC includes praziquantel or albendazole. Praziquantel 
is a pyrazino-isoquinoline derivative that affects calcium channels on the parasite’s 
surface and causes muscle contractions, paralysis, and tegument damage [11]. 
Maximum serum levels of praziquantel are obtained in 1.5–2 h after administration 
[12]. Praziquantel is metabolized in the liver, and its mild side effects include gastric 
disturbances, dizziness, drowsiness, fever, headache, increased sweating, and 
sometimes allergic reactions; however, these reactions disappear when the drug is 
withdrawn [13]. Albendazole is a benzimidazole compound that leads to the selec-
tive degeneration of cytoplasmic microtubules, affecting the formation of ATP, and 
glucose intake, which depletes parasite of the energy source [14]. Maximum serum 
levels of albendazole are achieved in 2 to 3 h after ingestion. This drug penetrates the 
cerebrospinal fluid better than praziquantel [15]. Side effects in humans are mainly 
related to liver toxicity (increased liver enzymes), hematological effects, hair loss, 
and general symptoms that dissipate when treatment is withdrawn [14]. The use of 
antiparasitic drugs can cause adverse effects arising from the inflammatory reac-
tion induced when cysticerci are damaged; therefore, the use of corticosteroids in 
addition to treatment is recommended. However, prolonged use of corticosteroids 
increases the risk of opportunistic infections, skin disorders, depression, osteope-
nia, among others [13]. Several drugs, including benzimidazole, praziquantel and 
nitazoxanide, have been evaluated for their ability to control swine cysticercosis in 
animals intended for consumption. Of these, oxfendazole has been shown to have 
close to 100% efficacy after a single dose in intramuscular cysticercosis, but the 
efficacy was lower in swine neurocysticercosis [16].
1.4 New drugs
Patients who do not respond to therapy with the currently available drugs have 
been reported. Several factors have been proposed that may be involved in this 
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lack of sensitivity to the treatment: differential response according to the state of 
development of cysticerci, low penetration of the drug into the subarachnoid space, 
variability of albendazole sulfoxide levels in plasma in individual patients, or inter-
ference of corticosteroids with the activity of anti-helmintics [17, 18]. This has led to 
the search for new drugs that could improve the effectiveness of the anti-helminthic 
therapy. Therefore, cytosolic glutathione transferases (cGSTs) have been selected as 
targets for the development of vaccines and drugs against this parasite [19–22].
2. Overview of glutathione transferases
2.1 The catalytic reaction
GSTs (EC 2.5.1.18) are a multiprotein family highly expressed in all cells [23, 24]. 
They are part of phase II detoxification process and catalyze the conjugation of glutathi-
one to a variety of endo- and exo-electrophilic substrates [25]. This conjugation produces 
soluble compounds and substrates for cellular export proteins, such as P-glycoprotein 
and multidrug resistance-related protein 1 [26]. The general reactions (GSH + RX → 
GSR + HX) comprise a nucleophilic attack, aromatic substitution, epoxide ring opening, 
reversible Michael addition, isomerization or peroxidation. Although nucleophilic attack 
can also be directed to nitrogen atoms in nitrate esters, sulfurs in organic thiocyanates or 
disulfites, and oxygen in organic hydroperoxides [25, 27–29].
2.2 Cellular distribution and GST classes
GSTs can be grouped into three subfamilies according to their cellular location: 
mitochondrial GSTs, microsomal GSTs or MAPEGs (membrane-associated proteins 
in eicosanoid and GSH metabolism), and cytosolic or canonical GSTs. In humans, 
genes encoding all expressed GSTs from a given subfamily are clustered on the 
same chromosome [30]. The mitochondrial GST subfamily includes a unique kappa 
(K) class. This class has very high peroxidase activity, and its location suggests an 
important role in β-oxidation of fatty acids and in lipid peroxidation. Moreover, it 
is also a key regulator of adiponectin biosynthesis and may function as a chaperone 
[31–34]. Microsomal GSTs are divided into four groups (I–IV). They share less 
than 20% sequence identity and are involved in eicosanoid metabolism, such as the 
synthesis of prostaglandins, thromboxanes, leukotrienes (inhibitors of inflamma-
tion), glutathione metabolism, and activation of some lipoxygenases [33, 35–37]. In 
the subfamily of cGSTs, members of the same class have more than 40% amino acid 
sequence identity, whereas sequence identity between classes is below 25%. cGSTs 
are divided into: (1) organism-specific GST classes, which include several GSTs, 
such as lambda (L), phi (F), and tau (U) in plants; delta (D), epsilon (E) in insects; 
beta (B) in prokaryotes; and 2) ubiquitous classes in any organism, including mu 
(M), alpha (A), pi (P), theta (T), sigma (S), zeta (Z), and omega (O) classes. Each 
of them displays distinct catalytic and non-catalytic binding properties, and their 
functions are very versatile and involve detoxification, signal modulation, catabo-
lism of aromatic amino acids, ion channel modulation, chemotherapy resistance, 
prostaglandin and steroid hormone synthesis, and transport of molecules such as 
bilirubin, heme, steroids, hormones, and bile salts [25, 27, 29, 31, 33, 38–43].
2.3 Structural characteristics
All cGSTs are dimers with 24–27 kDa monomeric subunits containing ~250 
amino acid residues on average. They share the same tertiary and quaternary 
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structures, and each subunit has two distinct functional domains. The first domain 
is the G site, which is located at the N-terminal region and is responsible for GSH 
binding. This domain is highly conserved in all classes and has a thioredoxin-like 
fold constructed by three helices and four sheets (βαβαββα). Activation of GSH 
occurs at the G-site by different amino acids, depending on the class, and is either 
a tyrosine (Y) found in M, P, A, and S-classes, a serine (S) found in T, Z, F, U, and 
D-classes, or a cysteine (C) to O, and B-classes. The activation allows a nucleophilic 
attack on the electrophilic compounds, allowing conjugation or thiol transfer. The 
first two amino acids, tyrosine and serine, promote the formation and stabiliza-
tion of the thiolate anion of GSH, lowering its pKa to 6.2. This is achieved through 
hydrogen bond donation of the hydroxyl group, which makes GSH ready for 
conjugation. The C residue is used for thiol transfer, and it forms mixed disulfides 
with GSH. The N-terminal domain consensus sequence SNAIL/TRAIL is localized 
in the region between residues 68 and 77, and appears in all mammalian cGSTs 
[25, 29, 31, 44, 45]. The second domain is the H site, which is localized in the 
C-terminal region. This domain binds the electrophilic substrate, and it is consti-
tuted exclusively by α-helices. The number of helices varies from four to seven, 
depending on the class. This variation has been used to explain the wide range 
of electrophilic substrates for detoxification and specificity among classes. For 
example, the M-class has very efficient catalysis with molecules containing oxiranes 
and unsaturated carbonyl groups, whereas A-class acts on 4-hydroxyalkenals and 
peroxides [20, 25, 31, 33, 45]. Although GSTs do not present specificity for their 
hydrophobic substrates, they seem very specific for the γ-glutamyl portion of GSH, 
and there is evidence that a peptide portion in the conjugate binds to ATP pumps or 
the multidrug resistance-associated proteins to be exported [46, 47]. Furthermore, 
in these domains, there are also conserved motifs that identify GST classes. For 
example, the primary and secondary structures that form the mu-loop or α9-helix 
are characteristic of M, and A-GST classes [20, 45, 48].
2.4 Alternative functions of GSTs
Besides their catalytic role, ligandin activity has been identified in GSTs because 
they bind toxic non-substrate ligands, such as hemin, bilirubin, bile salts, steroids, 
thyroid hormones, fatty acids, drugs (albendazole and praziquantel), and members 
of the MAPK protein kinase family, which are involved in processes such as the 
production, storage, and rapid transport of prostaglandins out of cells, intrinsic 
and acquired drug resistance, cell survival and apoptosis, contributing to passive 
detoxification or intracellular transport in cells. The ligandin site is different from 
the G and H sites, and the above-mentioned toxic non-substrates are able to inhibit 
the catalytic activity of GSTs [49–52]. Another striking property of the GST enzyme 
is its translocation from the outside to the inside of various cells. This internaliza-
tion occurs through endocytosis mediated by receptors or by the GST-fold struc-
ture, and it is independent of GST function as an enzyme [53, 54].
2.5 GSTs in platyhelminthes
In these parasites, GSTs also act as xenobiotic detoxifying enzymes, catalyzing 
conjugation of GSH (active detoxification) or, in the case of ligandin, transporting 
toxic substrates (passive detoxification) and acting as protective antigens to the host 
[23, 55]. Finally, many reports on vaccination experiments have described reduc-
tions in parasite burden, fecal egg counts, tissue egg densities, and female fecundity 
in experimental cysticercosis, schistosomiasis, and fascioliasis [23, 56–60]. The 
World Health Organization has recommended the use of Schistosoma japonicum 
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GST (SjGST) as a vaccine antigen in the form of a DNA vaccine (pcDNA/sjGST) in 
nanoparticles combined with pIL-12 [61, 62].
2.6 GSTs in T. solium
In the cestode T. solium, GST activity has been identified in the microsomal frac-
tion, and it was noncompetitively inhibited by triphenyltin chloride and bromo-
sulfophthalein [63]. Moreover, three cGSTs classes have been identified according 
to the classification of mammalian GSTs [20]: (i) a moderately abundant S-class 
GST denoted as TsMσGST, (ii) the least abundant M-class GST named Ts25GST 
(previously referred to as SGSTM1), which has a high capacity to conjugate reactive 
carbonyls, the secondary products of lipid peroxidation, and (iii) the most abun-
dant M and A-class GST named Ts26GST (previously referred to as SGSTM2). The 
characteristics and properties of these enzymes are listed in Table 1.
The specific antibodies produced against each TsGST (TsMσGST, Ts25GST, 
and Ts26GST) showed that they are not antigenically related to each other, nor to 
trematode, cestode, or mammalian GSTs [19, 20, 64]. Interestingly, these specific 
antibodies recognized the homologous GST class in T. saginata, T. taeniaeformis, and 
T. crassiceps. On the other hand, immunizations of a murine model of cysticercosis 
with the SGSTF fraction purified from cysticerci (comprising both Ts25GST and 
Ts26GST) or with recombinant Ts26GST alone were highly effective in reducing 
cysticerci load by 90% and 74%, respectively, whereas the use of the native and 
recombinant Ts25GST as immunogens afforded lower protection rates, 46% and 
25%, respectively [19].
The aforementioned result as well as the known lack of catalase and low activi-
ties of CYP450 and glutathione peroxidase have led us to postulate that GSTs are the 
major detoxification system for this parasite. In addition, the properties of cGSTs 
as immunogens and vaccination candidates make them attractive targets for the 
development of new drugs against this parasite [19, 20, 22, 64].
Anti-helminthic compounds such as mebendazole and praziquantel inhibited 
Ts26GST and TsMσGST in vitro, but they did not reach plasma concentrations in vivo 
that would allow effective inhibition of enzyme activity [20, 64, 65, 66]. To date, a 
TsMσGST Ts25GST Ts26GST
Number of amino acids 212 219 221
Molecular mass (Da) 24,290 25,496 25,936
Number of isoforms 4 2 4
Isoelectric point 8.2–8.7 5.7–6.3 7.2–8.5
Vmax(CDNB) (μmol min
−1 mg−1) 1.08 12.0 51.5
KM(CDNB) (mM) 0.16 1.38 1.06
Vmax(GSH) (μmol min
−1 mg−1) 0.78 10.2 39.9
KM(GSH) (mM) 0.17 0.905 0.20
Classes of effective inhibitors A, M A, M A, M
Optimal conditions pH 8.0, 
40 °C
pH 8.0, 37–40°C pH 7–5, 37–40°C
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Figure 1. 
Alignment of the amino acid sequences of Ts26GST with representatives of different human GST classes. The 
percent identity matrix shows that Ts26GST is most related to human M-class GST (m1).
non-toxic inhibitor for GST has not been developed, but ethacrynic acid, haloenol 
lactone, disulfiram, and curcumin are potent inhibitors of human GST-P1 [67, 68]. 
A new generation of drugs, such as modified ethacrynic acid, γ-glutamyl-S-(benzyl)
cysteinyl-R(−)-phenyl glycine diethyl ester (TER 199), and prodrug (TER 286), pro-
vide a starting point for development of novel powerful and specific inhibitors against 
human GST-P1. However, the clinical side effects have limited their application [24].
3. Kinetic and structural properties of Ts26GST
3.1 Kinetic mechanism of Ts26GST in the CDNB conjugation reaction
Ts26GST is a bisustrate enzyme that exhibits a higher affinity for glutathione 
(GSH) than for 1-chloro-2,4-dinitrobenzene (CDNB), unlike other two cGSTs of 
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T. solium (see Table 1). Furthermore, the kinetic curves for both substrates showed 
positive cooperativity, indicating that the binding of the first substrate stabilizes 
the right conformation of Ts26GST to bind the second substrate [21]. This positive 
cooperativity, previously described for the GSTs of P. falciparum and in classes P1 
and Z1 of mammals, allows the parasite to adapt to changes in the amounts of toxic 
molecules secreted by the host’s immune cells or induced by oral drugs, and to 
inactivate them through efficient processing of these substrates [69].
Kinetic analyses performed at different concentrations of GSH and CDNB 
produced intersecting double-reciprocal plots that provided evidence of ternary 
complex formation during enzymatic conjugation [70]. Furthermore, because the 
intersection occurred on the abscissa, the mechanism proceeds through the random 
sequential binding of co-substrates [71].
To determine the GST class to which Ts26GST belongs, various class marker sub-
strates and inhibitors were tested. Ts26GST conjugates the A-class markers cumene 
hydroperoxide and ethacrynic acid better than the M-class marker 1,2-dichloro-
4-nitrobenzene [20]. However, Ts26GST is more sensitive to the M-class inhibitors 
cibacron blue and triphenyltin chloride than to bromosulfophtalein, an A-class 
inhibitor. This enzyme is also sensitive to the anthelminthic mebendazole, display-
ing a non-competitive inhibition pattern, which suggests that at least two molecules 
bind to Ts26GST [21].
3.2 Structural similarity of Ts26GST to human cGSTs
Multiple amino acid sequence alignments of Ts26GST with all classes of human 
cGSTs are shown in Figure 1. It can be seen from the percent identity matrix that 
the primary structure of Ts26GST is closely related to M-class (42% sequence 
identity) and A-class (27% sequence identity) but is more distant from other 
human GST classes. The G-site of Ts26GST belongs to class Y, with Y8 being the 
catalytic residue that activates GSH. This site also has the essential conserved 
residues for γ-glutamyl binding: P(57), Q(68), and S(69). The last two residues 
are part of the (Q )SHVIT sequence, which in mammalian GSTs constitutes the 
consensus motif (Q )SNAIL /(Q )TRAIL. Notably, amino acid variation in this 
consensus motif is one of the markers for distinguishing between mammalian and 
Figure 2. 
Modeled structure of Ts26GST. (A) The domain with the site where glutathione binds, is highlighted in green, 
and the domain with the hydrophobic site, to which electrophilic substrates bind, is highlighted in gray.  
(B) The structure of Ts26GST in white is compared to human A-class GST structure (blue) and M-class 
structure (brown).
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Figure 3. 
Putative binding site for TS26GST inhibitors whose occupancy could produce non-competitive inhibition. Just 
one subunit is represented with van der Waals surface for clarity. Bound GSH and CDNB molecules are shown 
in orange and magenta, respectively, whereas the spheres represent the space that the ligand could occupy.
parasite cGSTs [20]. Ts26GST has ligandin activity and is internalized by macro-
phages, suggesting an important role in transport and the parasite–host  
relationship [72, 73].
A homology model for Ts26GST was built from the structure of Fasciola hepatica 
M-class GST (PDB ID 2FHE), whose sequence has 47% identity, with 96% query 
coverage [70]. The analysis of this model with PROCHECK showed that 91.5% of 
residues are in favored regions in the Ramachandran plot, with no residues in the 
disallowed region. In addition, verification with ERRAT yielded an Overall Quality 
Factor of 93.55 and the Verify3D score was 95.18. A comparison of the Ts26GST 
model with M and A-class human GST structures is shown in Figure 2. It is clear 
that Ts26GST does not have the classical mammalian mu-loop or the canonical 
α9-helix observed in A-class GSTs.
4. Structure-based discovery of Ts26GST selective inhibitors
4.1  Search and selection of cavities with non-conserved residues as potential 
targets
Knowing the structure of the target whose activity we wish to inhibit is an essen-
tial step for the discovery and optimization of specific inhibitors. Furthermore, if 
the target is a parasitic enzyme, and the host has orthologs, knowing and comparing 
their structures allows us to take advantage of their differences and design more 
specific inhibitors [74]. Different strategies have been used to find appropriate 
inhibitors, and we decided to look for a non-competitive inhibitor that cannot be 
displaced by excess substrate, i.e., the one that would not bind to either the G-site 
or the H-site. Thus, we focused our search on the area of the dimer interface, trying 
to find a site whose occupation would alter the architecture of at least one of the 
substrate sites and prevent catalysis. Furthermore, the binding of a molecule in this 
interfacial region could destabilize the quaternary structure of this enzyme, which 
is only active as a dimer. Likewise, we assumed that the site has a predominantly 
hydrophobic surface and contains a considerable fraction of non-conserved residues 
with respect to its human orthologs. Using the MOE’s Site Finder tool [75], we found 
only one site that met all these requirements; its location is shown in Figure 3.
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4.2 Virtual screening with a commercial diverse library set
Once a potential inhibitor binding site has been located, we must find molecules 
that conform to its surface and interact favorably to form stable complexes. To 
explore how to cover this site in the chemical space, we used Enamine’s library 
of non-redundant organic compounds called the Discovery Diversity Set, which 
consists of 50,240 drug-like compounds, and performed virtual screening using 
AutoDock Vina [76]. The scores of the best candidates were verified using MOE’s 
Dock Tool [75].
4.3 Assortment of candidates
The best putative binders for Ts26GST were selected using the conventional 
criteria: the highest docking scores, the highest number of hydrogen bonds, and 
Lipinski’s rule of five [77], but in addition, those ligands were prioritized that 
established the lowest number of contacts with conserved residues in relation to 
human GSTs. The best 23 candidates are shown in Figure 4 and their docking scores 
obtained using AutoDock Vina and MOE are given in Table 2.
Figure 4. 
Best candidate inhibitors found by virtual screening.
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Compound Enamine ID Chemical formula Docking score vina/moe *Residual 
activity (%)
I1 Z30971507 C26H28N4O4S −9.6/−11.1 92
I2 Z26762460 C26H27N3O4S −10.0/−10.4 129
I3 Z27434387 C22H21FN4O3S2 −9.4/−10.1 98
I4 Z109818646 C25H29FN4O3S −9.4/−11.0 120
I5 Z27205337 C27H29N3O4S −9.5/−10.3 82
I6 Z235256042 C24H27N5O4S −10.0/−10.3 74
I7 Z56803795 C19H19N3O4 −9.9/−9.7 30
I8 Z98069587 C24H28N4O4S −9.9/−9.7 107
I9 Z51980171 C25H35N3O4S −9.5/−10.8 76
I10 Z744434314 C20H22FN3O3 −9.4/−10.2 135
I11 Z231257554 C23H25N3O3S2 −9.5/−10.0 83
I12 Z109816768 C26H29N5O3S −9.9/−9.8 117
I13 Z225448008 C25H23N3O3 −9.4/−10.1 55
I14 Z283658802 C22H24N4O3 −9.7/−8.8 115
I15 Z512929356 C26H27N5O3 −9.8/−9.3 114
I16 Z131580092 C25H27N3O3 −9.7/−9.9 108
I17 Z90661741 C20H13FN4O2 −9.8/−8.5 116
I18 Z134793448 C23H24N2O5S −9.9/−10.3 66
I19 Z317185036 C23H28N4O2S −9.9/−10.0 113
I20 Z30996502 C24H24ClN5O2 −9.4/−10.6 72
I21 Z26496603 C25H27N3O5S −9.9/−11.5 78
I22 Z55180729 C23H23N5O4S2 −9.6/−9.9 88
I23 Z30414302 C23H27N5O3S2 −9.7/−10.0 82
*Residual activity of 5 μg of recombinant Ts26GST in presence of 100 μM of potential inhibitors.
Table 2. 
Docking scores of the predicted potential inhibitors determined using Vina and MOE_Dock. The inhibitory 
capacity of the compounds was determined by measuring the enzymatic activity of T26GST in the presence of 
each compound at a concentration of 100 μM, with 5.0 mM GSH and 2.5 mM CDNB. The reaction rate was 
monitored by ultraviolet–visible absorption at 340 nm and compared with that obtained in the absence of the 
compound (100% activity).
Figure 5. 
Relative position of the substrates GSH (orange) and CDNB (magenta), and the inhibitor I7 (red) in the 
structure of Ts26GST. (A) This figure was obtained by the superposition of the crystallographic structures of 
the complex M-class GS-DNB-HsGST (PDB ID: 1XWK) with the modeled complex of Ts26GST-I7, hiding 
the protein chain of the human GST. (B) Percent residual activity of Ts26GST and three human GSTs in the 
presence of 100 μM I7.
Please use Adobe Acrobat Reader to r ad this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing C nnection...croba  is locking documen loading.com
r
File cannot be found.
11
Development of New Drugs to Treat Taenia solium Cysticercosis: Targeting 26 kDa Glutathione…
DOI: http://dx.doi.org/10.5772/intechopen.97342
4.4 In vitro assay of selected compounds with the best scores
The twenty-three compounds previously identified as potential ligands of 
Ts26GST were purchased and tested for their inhibitory activity using in vitro enzy-
matic assays. Table 2 shows the residual activity obtained with 5.0 μg of recom-
binant Ts26GST in the presence of each compound at a concentration of 100 μM. 
I7 was the best Enamine compound that inhibited enzymatic activity of Ts26GST 
by 70%. Figure 5A shows the location of the I7 binding site, as derived from the 
docking protocol. We also tested the inhibitory effect of I7 on several human GSTs 
and observed that it had much smaller or no effect (Figure 5B).
5. Conclusions
Human NCC caused by T. solium larvae can be asymptomatic, disabling, and 
sometimes fatal. Currently, its diagnosis and treatment are expensive, and the 
approved drugs have associated unwanted effects. The search for the essential 
targets in T. solium, such as GST, and the methodology used to obtain the inhibitor 
I7 and its derivatives, shows that it is possible to develop safe, specific, and effective 
drugs that will contribute to eradicating this parasite. We are currently working on 
the crystallization of Ts26GST and site-directed mutagenesis to verify the location 
of the I7 binding site.
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